Gareth Jones

Gareth Jones

Auto-generated profile, based on publicly available information

Gareth Jones

Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Neurobiology of Aging
Verified
Journal Article
Closed access
CRChristopher C. Rowe
Christopher C. Rowe
KEKathryn A. Ellis
Kathryn A. Ellis
MRMiroslava Rimajova
Miroslava Rimajova
PBPierrick Bourgeat
Pierrick Bourgeat
KPKerryn E. Pike
Kerryn E. Pike
VVVictor L. Villemagne
Victor L. Villemagne

28 January 2011 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
VVVictor L. Villemagne
Victor L. Villemagne
KPKerryn E. Pike
Kerryn E. Pike
GCGaël Chételat
Gaël Chételat
KEKathryn A. Ellis
Kathryn A. Ellis
RMRachel S. Mulligan
Rachel S. Mulligan
CRChristopher C. Rowe
Christopher C. Rowe

1 February 2008 in The Lancet Neurology
Verified
Journal Article
Closed access
CRChristopher C Rowe
Christopher C Rowe
UAUwe Ackerman
Uwe Ackerman
WBWilliam Browne
William Browne
RMRachel Mulligan
Rachel Mulligan
KPKerryn L Pike
Kerryn L Pike
VVVictor L Villemagne
Victor L Villemagne

29 March 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GCGaël Chételat
Gaël Chételat
VVVictor L. Villemagne
Victor L. Villemagne
PBPierrick Bourgeat
Pierrick Bourgeat
KPKerryn E. Pike
Kerryn E. Pike
GJGareth Jones
Gareth Jones
AGAustralian Imaging Biomarkers and Lifestyle Research Group
Australian Imaging Biomarkers and Lifestyle Research Group

15 July 2011 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
VVVictor L. Villemagne
Victor L. Villemagne
KOKevin Ong
Kevin Ong
RMRachel S. Mulligan
Rachel S. Mulligan
GHGerhard Holl
Gerhard Holl
SPSvetlana Pejoska
Svetlana Pejoska
CRChristopher C. Rowe
Christopher C. Rowe
Amyloid imaging with 18F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using 18F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD). Methods: One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of 18F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection. Results: When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P < 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical 18F-florbetaben retention. In contrast, only 9% of FTLD, 25% of VaD, 29% of DLB, and no PD patients and 16% of controls showed cortical binding. Although there was a correlation between Mini Mental State Examination and β-amyloid burden in the MCI group, no correlation was observed in controls, FTLD or AD. Conclusion: 18F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with 11C-Pittsburgh Compound B in a variety of neurodegenerative diseases.

16 September 2009 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SLSeok Ming Lim
Seok Ming Lim
AKAndrew Katsifis
Andrew Katsifis
VVVictor L. Villemagne
Victor L. Villemagne
RBRene Best
Rene Best
GJGareth Jones
Gareth Jones
CRChristopher C. Rowe
Christopher C. Rowe
Neuroimaging is increasingly used to supplement the clinical diagnosis of dementia with Lewy bodies (DLB) by showing reduced occipital metabolism and perfusion and reduced striatal dopaminergic innervation. We aimed to optimize the interpretation of 18F-FDG PET images for differentiating DLB from Alzheimer disease (AD) and to compare the results with dopamine transporter imaging using 123I-β-carbomethoxy-3ß-(4-iodophenyl)tropane (123I-β-CIT) SPECT. Methods: Fourteen subjects with a clinical diagnosis of DLB and 10 with AD underwent both 18F-FDG PET and 123I-β-CIT SPECT. Four DLB and 1 AD diagnoses were subsequently confirmed at autopsy. Diagnostic accuracy was calculated for visual interpretation by 3 readers of standard 3-plane and stereotactic surface projection 18F-FDG PET images, receiver-operating-characteristic analysis of regional 18F-FDG uptake, and a cutoff value for the striatal-to-occipital binding ratio of β-CIT defined by receiver-operating-characteristic analysis. Results: Visual interpretation of 3-plane 18F-FDG PET images had a sensitivity of 83% and specificity of 93% for DLB, slightly higher than the results with the stereotactic surface projection images. Regionally, hypometabolism in the lateral occipital cortex had the highest sensitivity (88%), but relative preservation of the mid or posterior cingulate gyrus (cingulate island sign) had the highest specificity (100%). Region-of-interest analysis revealed that occipital hypometabolism and relative preservation of the posterior cingulate both had a sensitivity of 77% and specificity of 80%. β-CIT achieved 100% accuracy and greater effect size than did 18F-FDG PET (Cohen d = 4.1 vs. 1.9). Conclusion: Both 18F-FDG PET and 123I-β-CIT SPECT appear useful for the diagnosis of DLB, although the latter provides more robust results. The cingulate island sign may enhance the specificity of 18F-FDG PET.